http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CY-1120117-T1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35dbc60da9891d57c4047fb7b8689516 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-595 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 |
| filingDate | 2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5deead4c8a935970e0588b21d02f6f9f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68bd1c97f491743410a8832db6943157 |
| publicationDate | 2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CY-1120117-T1 |
| titleOfInvention | GASTRINI'S MINI ANALOG, MORE SPECIFIED FOR USE IN DIAGNOSIS AND / OR CCK2 TUMOR TREATMENT TREATMENT |
| abstract | It is an object of the present invention to provide a gastrin analogue which exhibits high uptake in CCK-2 positive receptor tumors with a very low concentration in the kidneys. This objective is accomplished according to the present invention by a PP-F11 mini-gastrin analogue having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y -Asp-Phe-NH2, where Y denotes an amino acid that replaces methionine and X denotes a peptide-bound group for the purpose of diagnosing and / or treating CCK-2 receptor-related diseases . In particular, very suitable compounds with respect to a high ratio of tumor to kidney are the mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine that can be readily oxidized which is a disadvantage for clinical application under GMP due to the forms that may occur. Consequently, the elimination of methionine at a lower affinity for oxidation which generally favors the ratio of tumor to kidney. In a preferred embodiment of the present invention methionine is replaced by norleucine. This so-called mini-gastrin PP-F11N currently has the best tumor-kidney ratio and is therefore the most promising candidate for clinical applications. |
| priorityDate | 2013-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.